The Effects of Torasemide on Patients with Chronic Heart Failure

CLINICAL RESEARCH
Bakhrom Alyavi, PhD, ScD¹, Muyassar Mukhamedova¹, Dina Arnopolskaya, PhD²

¹Republican Specialized Scientific-Practical Medical Center of Therapy and Medical Rehabilitation, Tashkent, Uzbekistan, ²ORION MEDICITY LLC, Tashkent, Uzbekistan

*Corresponding author: Muyassar Mukhamedova, Republican Specialized Scientific-Practical Medical Center of Therapy and Medical Rehabilitation. 4, Osiyo street, Yunusabad district, 100084, Tashkent, Republic of Uzbekistan. Fax/Tel: 998-90-1898300/998-90-9100804. E-mail: muyassar1983@mail.ru

Published: March 25, 2013

Abstract: 

This article describes the effects of the additional application of torasemide in 22 patients with chronic heart failure of ischemic origin. It is indicated that torasemide application helps reduce the natriuretic peptide level and improves the central hemodynamics without a significant effect on the blood electrolyte level.

Keywords: 
chronic heart failure; natriuretic peptide; torasemide.
References: 
  1. Makolkin V. Features of the modern treatment of chronic heart failure. http://medinfa.ru/article/7/118619/. [in Russian].
  2. Karpov YuA. Angiotensin-receptor blockers: use in heart failure. RMJ 2002; 2:51-54. [in Russian].
  3. Arakawa N, Nakamura M, Aoki H, Hiramori K. Plasma brain natriuretic peptide concentrations predict survival after acute MI . J Am Coll Cardiol 1996; 27(7):1656-61.
  4. Dobrek Ł, Thor P. Neuroendocrine activation as a target of modern chronic heart failure pharmacotherapy. Acta Pol Pharm 2011; 68(3): 307-16.
  5. Packer M. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? J Am Coll Cardiol 1996; 28(5):1323-7.
  6. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981; 91(3):457-465.
  7. Ovchinnikov A.  Recent advances in the diagnosis of heart failure by the level of natriuretic peptide. Heart failure 2003; 4(3):158-160.
  8. Apple FS, Panteghini M, Ravkilde J. Mair J, Wu AH, Tate J, et al. Committee on standardization of makers of cardiac damage of the IFCC. Quality specifications for B-type natriuretic peptide assays. Clin Chem 2005; 51:486-493.
  9. Bоlke T, Achhammer I. Torasemide: review of its pharmacology and therapeutic use. Drugs of today 1994; 8:1-28.

The fully formatted PDF version is available.

Download Article

Int J Biomed. 2013; 3(1):20-22. © 2013 International Medical Research and Development Corporation. All rights reserved.